I always end my ‘Recent Buys’ posts with the caveat that Mr. Market can always spring up some new opportunities not outlined in my monthly considerations posts. Generally speaking, my ‘considerations’ posts offer a pretty solid road map for potential purchases I’d like to make in the upcoming month, and since I have started blogging I have stuck to my own recommendations almost all the time. Of course, in recent weeks and days for that matter, some solid, otherwise less compelling buys have become a lot more attractive. I think you all know the names.
For a few weeks we have seen the likes of Wells Fargo & Co. (NYSE:WFC) take a beating for obvious reasons, as well as other financial names such as T. Rowe Price Group, Inc (TROW) near their 52-week-lows. Consumer staples dividend stalwart VF Corp (NYSE:VFC) has not been spared either, closing just a few points above its 52-week-low, as did Unilever plc (ADR) (NYSE:UL) as well.
Then we had the most recent bombshells occur in the health sector with AbbVie Inc (NYSE:ABBV), Cardinal Health Inc. (NYSE:CAH), McKesson Corporation (NYSE:MCK) and AmerisourceBergen Corp. (NYSE:ABC) all nosediving over drug pricing. It’s at times like these that one must pause, take a breath and simply ride out the storm. Sure, in the near-term it can be scary to see some of your holdings gyrate wildly, but one must differentiate the noise from the reality. Personally, I do not see any of these businesses changing fundamentally long-term. The financial sector was vilified after 2009 and has bounced back quite handsomely since, even in the face of increased regulation and interest rates that headed to near zero. Long-term I see the entire health sector with a pervasive tailwind. Will there be some turbulence along the way? Of course, but the course remains unchanged. My question to you, as you read the dozens of articles written after this bloodbath telling you to steer clear of the sector, is where was all this insight beforehand? The talking heads love to write articles and produce videos after the fact. The reality is that no one saw this coming. All you can do as an individual dividend investor is tune out the noise, stay diversified among your holdings and make sure the dividend remains covered. OK. On to the reason you clicked on this post:
I have added to my taxable account 19.0000 shares at $57.53 for a total investment of $1,093.07 in AbbVie Inc (NYSE:ABBV). With this recent purchase my taxable account holdings in ABBV now totals 125.2220 shares for a market value of $7,212.79.
I have added to my taxable account 16.0000 shares at $66.17 for a total investment of $1,058.72 in Cardinal Health Inc. (NYSE:CAH). With this recent purchase my taxable account holdings in CAH now totals 21.0298 shares for a value of $1,419.51.
I have added to my ROTH account 9.0000 shares at $53.96 for a total investment of $485.64 in VF Corp (NYSE:VFC). This is a new position in my ROTH account. I also hold 40.0084 shares in my taxable account with a market value of $2,173.26.
What do you think about my recent buys? Have you been buying up some solid dividend payers at much better prices, values and yields recently? Please let me know below.
Disclosure: Long WFC, TROW, UL, VFC, CAH, ABBV
Note: This article is written by DivHut. Check out more of the site’s dividend investing content at divhut.com.